Hsp104 Suppresses Polyglutamine-Induced Degeneration Post Onset in a Drosophila MJD/SCA3 Model

English version České info

There are no effective therapeutics that antagonize or reverse the protein-misfolding events underpinning polyglutamine (PolyQ) disorders, including Spinocerebellar Ataxia Type-3 (SCA3). Here, we augment the proteostasis network of Drosophila SCA3 models with Hsp104, a powerful protein disaggregase from yeast, which is bafflingly absent from metazoa. Hsp104 suppressed eye degeneration caused by a C-terminal ataxin-3 (MJD) fragment containing the pathogenic expanded PolyQ tract, but unexpectedly enhanced aggregation and toxicity of full-length pathogenic MJD. Hsp104 suppressed toxicity of MJD variants lacking a portion of the N-terminal deubiquitylase domain and full-length MJD variants unable to engage polyubiquitin, indicating that MJD-ubiquitin interactions hinder protective Hsp104 modalities. Importantly, in staging experiments, Hsp104 suppressed toxicity of a C-terminal MJD fragment when expressed after the onset of PolyQ-induced degeneration, whereas Hsp70 was ineffective. Thus, we establish the first disaggregase or chaperone treatment administered after the onset of pathogenic protein-induced degeneration that mitigates disease progression.

Vyšlo v časopise: Hsp104 Suppresses Polyglutamine-Induced Degeneration Post Onset in a Drosophila MJD/SCA3 Model. PLoS Genet 9(9): e32767. doi:10.1371/journal.pgen.1003781
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1003781

Souhrn

Zdroje

1. FormanMS, TrojanowskiJQ, LeeVM (2004) Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 10: 1055–1063.

2. ChitiF, DobsonCM (2006) Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75: 333–366.

3. CushmanM, JohnsonBS, KingOD, GitlerAD, ShorterJ (2010) Prion-like disorders: blurring the divide between transmissibility and infectivity. J Cell Sci 123: 1191–1201.

4. WestermarkP, BensonMD, BuxbaumJN, CohenAS, FrangioneB, et al. (2005) Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 12: 1–4.

5. DeSantisME, LeungEH, SweenyEA, JackrelME, Cushman-NickM, et al. (2012) Operational plasticity enables hsp104 to disaggregate diverse amyloid and nonamyloid clients. Cell 151: 778–793.

6. TessarzP, MogkA, BukauB (2008) Substrate threading through the central pore of the Hsp104 chaperone as a common mechanism for protein disaggregation and prion propagation. Mol Microbiol 68: 87–97.

7. WendlerP, ShorterJ, PlissonC, CashikarAG, LindquistS, et al. (2007) Atypical AAA+ subunit packing creates an expanded cavity for disaggregation by the protein-remodeling factor Hsp104. Cell 131: 1366–1377.

8. WendlerP, ShorterJ, SneadD, PlissonC, ClareDK, et al. (2009) Motor mechanism for protein threading through Hsp104. Mol Cell 34: 81–92.

9. SanchezY, LindquistSL (1990) HSP104 required for induced thermotolerance. Science 248: 1112–1115.

10. ParsellDA, KowalAS, SingerMA, LindquistS (1994) Protein disaggregation mediated by heat-shock protein Hsp104. Nature 372: 475–478.

11. AlbertiS, HalfmannR, KingO, KapilaA, LindquistS (2009) A systematic survey identifies prions and illuminates sequence features of prionogenic proteins. Cell 137: 146–158.

12. ShorterJ, LindquistS (2004) Hsp104 catalyzes formation and elimination of self-replicating Sup35 prion conformers. Science 304: 1793–1797.

13. ShorterJ, LindquistS (2006) Destruction or potentiation of different prions catalyzed by similar Hsp104 remodeling activities. Mol Cell 23: 425–438.

14. RampeltH, Kirstein-MilesJ, NillegodaNB, ChiK, ScholzSR, et al. (2012) Metazoan Hsp70 machines use Hsp110 to power protein disaggregation. EMBO J 31: 4221–4235.

15. ShorterJ (2011) The mammalian disaggregase machinery: Hsp110 synergizes with Hsp70 and Hsp40 to catalyze protein disaggregation and reactivation in a cell-free system. PLoS One 6: e26319.

16. DuennwaldML, EcheverriaA, ShorterJ (2012) Small heat shock proteins potentiate amyloid dissolution by protein disaggregases from yeast and humans. PLoS Biol 10: e1001346.

17. VashistS, CushmanM, ShorterJ (2010) Applying Hsp104 to protein-misfolding disorders. Biochem Cell Biol 88: 1–13.

18. ShorterJ (2008) Hsp104: a weapon to combat diverse neurodegenerative disorders. Neurosignals 16: 63–74.

19. BettencourtC, LimaM (2011) Machado-Joseph Disease: from first descriptions to new perspectives. Orphanet J Rare Dis 6: 35.

20. PaulsonH (2012) Machado-Joseph disease/spinocerebellar ataxia type 3. Handb Clin Neurol 103: 437–449.

21. PaulsonHL, DasSS, CrinoPB, PerezMK, PatelSC, et al. (1997) Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain. Ann Neurol 41: 453–462.

22. PaulsonHL, PerezMK, TrottierY, TrojanowskiJQ, SubramonySH, et al. (1997) Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 19: 333–344.

23. TakiyamaY, NishizawaM, TanakaH, KawashimaS, SakamotoH, et al. (1993) The gene for Machado-Joseph disease maps to human chromosome 14q. Nat Genet 4: 300–304.

24. WinbornBJ, TravisSM, TodiSV, ScaglioneKM, XuP, et al. (2008) The deubiquitinating enzyme ataxin-3, a polyglutamine disease protein, edits Lys63 linkages in mixed linkage ubiquitin chains. J Biol Chem 283: 26436–26443.

25. KuhlbrodtK, JanieschPC, KeveiE, SegrefA, BarikbinR, et al. (2011) The Machado-Joseph disease deubiquitylase ATX-3 couples longevity and proteostasis. Nat Cell Biol 13: 273–281.

26. MasinoL, MusiV, MenonRP, FusiP, KellyG, et al. (2003) Domain architecture of the polyglutamine protein ataxin-3: a globular domain followed by a flexible tail. FEBS Lett 549: 21–25.

27. EllisdonAM, PearceMC, BottomleySP (2007) Mechanisms of ataxin-3 misfolding and fibril formation: kinetic analysis of a disease-associated polyglutamine protein. J Mol Biol 368: 595–605.

28. EllisdonAM, ThomasB, BottomleySP (2006) The two-stage pathway of ataxin-3 fibrillogenesis involves a polyglutamine-independent step. J Biol Chem 281: 16888–16896.

29. MasinoL, NicastroG, MenonRP, Dal PiazF, CalderL, et al. (2004) Characterization of the structure and the amyloidogenic properties of the Josephin domain of the polyglutamine-containing protein ataxin-3. J Mol Biol 344: 1021–1035.

30. ShorterJ, LindquistS (2008) Hsp104, Hsp70 and Hsp40 interplay regulates formation, growth and elimination of Sup35 prions. EMBO J 27: 2712–2724.

31. Lo BiancoC, ShorterJ, RegulierE, LashuelH, IwatsuboT, et al. (2008) Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. J Clin Invest 118: 3087–3097.

32. PerrinV, RegulierE, Abbas-TerkiT, HassigR, BrouilletE, et al. (2007) Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease. Mol Ther 15: 903–911.

33. SatyalSH, SchmidtE, KitagawaK, SondheimerN, LindquistS, et al. (2000) Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proc Natl Acad Sci U S A 97: 5750–5755.

34. VacherC, Garcia-OrozL, RubinszteinDC (2005) Overexpression of yeast hsp104 reduces polyglutamine aggregation and prolongs survival of a transgenic mouse model of Huntington's disease. Hum Mol Genet 14: 3425–3433.

35. Dandoy-DronF, BogdanovaA, BeringueV, BaillyY, ToveyMG, et al. (2006) Infection by ME7 prion is not modified in transgenic mice expressing the yeast chaperone Hsp104 in neurons. Neurosci Lett 405: 181–185.

36. MosserDD, HoS, GloverJR (2004) Saccharomyces cerevisiae Hsp104 enhances the chaperone capacity of human cells and inhibits heat stress-induced proapoptotic signaling. Biochemistry 43: 8107–8115.

37. TrinhK, MooreK, WesPD, MuchowskiPJ, DeyJ, et al. (2008) Induction of the phase II detoxification pathway suppresses neuron loss in Drosophila models of Parkinson's disease. J Neurosci 28: 465–472.

38. BrandAH, PerrimonN (1993) Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development 118: 401–415.

39. RitsonGP, CusterSK, FreibaumBD, GuintoJB, GeffelD, et al. (2010) TDP-43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97. J Neurosci 30: 7729–7739.

40. WarrickJM, PaulsonHL, Gray-BoardGL, BuiQT, FischbeckKH, et al. (1998) Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell 93: 939–949.

41. WarrickJM, MorabitoLM, BilenJ, Gordesky-GoldB, FaustLZ, et al. (2005) Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. Mol Cell 18: 37–48.

42. HaackeA, HartlFU, BreuerP (2007) Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3. J Biol Chem 282: 18851–18856.

43. JungJ, XuK, LessingD, BoniniNM (2009) Preventing Ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3. Hum Mol Genet 18: 4843–4852.

44. CummingsCJ, ManciniMA, AntalffyB, DeFrancoDB, OrrHT, et al. (1998) Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat Genet 19: 148–154.

45. WarrickJM, ChanHY, Gray-BoardGL, ChaiY, PaulsonHL, et al. (1999) Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat Genet 23: 425–428.

46. ChanHY, WarrickJM, Gray-BoardGL, PaulsonHL, BoniniNM (2000) Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in Drosophila. Hum Mol Genet 9: 2811–2820.

47. MuchowskiPJ, SchaffarG, SittlerA, WankerEE, Hayer-HartlMK, et al. (2000) Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc Natl Acad Sci U S A 97: 7841–7846.

48. HalfmannR, LindquistS (2008) Screening for amyloid aggregation by Semi-Denaturing Detergent-Agarose Gel Electrophoresis. J Vis Exp 17: e838 doi:810.3791/3838

49. SanchezY, ParsellDA, TaulienJ, VogelJL, CraigEA, et al. (1993) Genetic evidence for a functional relationship between Hsp104 and Hsp70. J Bacteriol 175: 6484–6491.

50. BettencourtC, SantosC, MontielR, Costa MdoC, Cruz-MoralesP, et al. (2010) Increased transcript diversity: novel splicing variants of Machado-Joseph disease gene (ATXN3). Neurogenetics 11: 193–202.

51. HarrisGM, DodelzonK, GongL, Gonzalez-AlegreP, PaulsonHL (2010) Splice isoforms of the polyglutamine disease protein ataxin-3 exhibit similar enzymatic yet different aggregation properties. PLoS One 5: e13695.

52. DiSalvoS, DerdowskiA, PezzaJA, SerioTR (2011) Dominant prion mutants induce curing through pathways that promote chaperone-mediated disaggregation. Nat Struct Mol Biol 18: 486–492.

53. RomanG, DavisRL (2002) Conditional expression of UAS-transgenes in the adult eye with a new gene-switch vector system. Genesis 34: 127–131.

54. OsterwalderT, YoonKS, WhiteBH, KeshishianH (2001) A conditional tissue-specific transgene expression system using inducible GAL4. Proc Natl Acad Sci U S A 98: 12596–12601.

55. JuS, TardiffDF, HanH, DivyaK, ZhongQ, et al. (2011) A yeast model of FUS/TLS-dependent cytotoxicity. PLoS Biol 9: e1001052.

56. ArmakolaM, HigginsMJ, FigleyMD, BarmadaSJ, ScarboroughEA, et al. (2012) Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models. Nat Genet 44: 1302–1309.

57. SunZ, DiazZ, FangX, HartMP, ChesiA, et al. (2011) Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. PLoS Biol 9: e1000614.

58. ShorterJ, LindquistS (2005) Prions as adaptive conduits of memory and inheritance. Nat Rev Genet 6: 435–450.

59. DeSantisME, ShorterJ (2012) Hsp104 drives “protein-only” positive selection of Sup35 prion strains encoding strong [PSI(+)]. Chem Biol 19: 1400–1410.

60. Nekooki-MachidaY, KurosawaM, NukinaN, ItoK, OdaT, et al. (2009) Distinct conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cytotoxicity. Proc Natl Acad Sci U S A 106: 9679–9684.

61. OlzschaH, SchermannSM, WoernerAC, PinkertS, HechtMH, et al. (2011) Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 144: 67–78.

62. VabulasRM, HartlFU (2011) Aberrant protein interactions in amyloid disease. Cell Cycle 10: 1512–1513.

63. DouglasPM, TreuschS, RenHY, HalfmannR, DuennwaldML, et al. (2008) Chaperone-dependent amyloid assembly protects cells from prion toxicity. Proc Natl Acad Sci U S A 105: 7206–7211.

64. WolfeKJ, CyrDM (2011) Amyloid in neurodegenerative diseases: friend or foe? Semin Cell Dev Biol 22: 476–481.

65. DobsonCM (2003) Protein folding and misfolding. Nature 426: 884–890.

66. CarmichaelJ, ChatellierJ, WoolfsonA, MilsteinC, FershtAR, et al. (2000) Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease. Proc Natl Acad Sci U S A 97: 9701–9705.

67. WellingtonCL, EllerbyLM, HackamAS, MargolisRL, TrifiroMA, et al. (1998) Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem 273: 9158–9167.

68. GrahamRK, DengY, SlowEJ, HaighB, BissadaN, et al. (2006) Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 125: 1179–1191.

69. DuennwaldML, JagadishS, MuchowskiPJ, LindquistS (2006) Flanking sequences profoundly alter polyglutamine toxicity in yeast. Proc Natl Acad Sci U S A 103: 11045–11050.

70. MasinoL, NicastroG, De SimoneA, CalderL, MolloyJ, et al. (2011) The Josephin domain determines the morphological and mechanical properties of ataxin-3 fibrils. Biophys J 100: 2033–2042.

71. NicastroG, MenonRP, MasinoL, KnowlesPP, McDonaldNQ, et al. (2005) The solution structure of the Josephin domain of ataxin-3: structural determinants for molecular recognition. Proc Natl Acad Sci U S A 102: 10493–10498.

72. MuchowskiPJ, WackerJL (2005) Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 6: 11–22.

73. BroadleySA, HartlFU (2009) The role of molecular chaperones in human misfolding diseases. FEBS Lett 583: 2647–2653.

74. ShenHY, HeJC, WangY, HuangQY, ChenJF (2005) Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice. J Biol Chem 280: 39962–39969.

75. McLeanPJ, KluckenJ, ShinY, HymanBT (2004) Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity in vitro. Biochem Biophys Res Commun 321: 665–669.

76. AuluckPK, BoniniNM (2002) Pharmacological prevention of Parkinson disease in Drosophila. Nat Med 8: 1185–1186.

77. WangAM, MiyataY, KlinedinstS, PengHM, ChuaJP, et al. (2012) Activation of Hsp70 reduces neurotoxicity by promoting polyglutamine protein degradation. Nat Chem Biol 9: 112–8.

78. BraakH, Del TrediciK, RubU, de VosRA, Jansen SteurEN, et al. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24: 197–211.

79. NaslundJ, HaroutunianV, MohsR, DavisKL, DaviesP, et al. (2000) Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283: 1571–1577.

80. DaviesSW, TurmaineM, CozensBA, DiFigliaM, SharpAH, et al. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90: 537–548.

81. BainbridgeJW, SmithAJ, BarkerSS, RobbieS, HendersonR, et al. (2008) Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358: 2231–2239.

82. Hacein-Bey-AbinaS, Le DeistF, CarlierF, BouneaudC, HueC, et al. (2002) Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346: 1185–1193.

83. MaguireAM, SimonelliF, PierceEA, PughENJr, MingozziF, et al. (2008) Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358: 2240–2248.

84. FeiginA, KaplittMG, TangC, LinT, MattisP, et al. (2007) Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc Natl Acad Sci U S A 104: 19559–19564.

85. KaplittMG, FeiginA, TangC, FitzsimonsHL, MattisP, et al. (2007) Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369: 2097–2105.

86. StoesslAJ (2007) Gene therapy for Parkinson's disease: early data. Lancet 369: 2056–2058.

87. SimonatoM, BennettJ, BoulisNM, CastroMG, FinkDJ, et al. (2013) Progress in gene therapy for neurological disorders. Nat Rev Neurol 9: 298.

88. San SebastianW, SamaranchL, KellsAP, ForsayethJ, BankiewiczKS (2013) Gene Therapy for Misfolding Protein Diseases of the Central Nervous System. Neurotherapeutics 10: 498–510.

89. SchiavoG, BenfenatiF, PoulainB, RossettoO, Polverino de LauretoP, et al. (1992) Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 359: 832–835.

90. YehFL, ZhuY, TeppWH, JohnsonEA, BerticsPJ, et al. (2011) Retargeted clostridial neurotoxins as novel agents for treating chronic diseases. Biochemistry 50: 10419–10421.

91. HallettM (1999) One man's poison–clinical applications of botulinum toxin. N Engl J Med 341: 118–120.

92. EsquenaziA, MayerNH, EliaAE, AlbaneseA (2009) Botulinum toxin for the management of adult patients with upper motor neuron syndrome. Toxicon 54: 634–638.

93. EliaAE, FilippiniG, CalandrellaD, AlbaneseA (2009) Botulinum neurotoxins for post-stroke spasticity in adults: a systematic review. Mov Disord 24: 801–812.

94. BentivoglioAR, AlbaneseA (1999) Botulinum toxin in motor disorders. Curr Opin Neurol 12: 447–456.

95. OsborneSL, LathamCF, WenPJ, CavaignacS, FanningJ, et al. (2007) The Janus faces of botulinum neurotoxin: sensational medicine and deadly biological weapon. J Neurosci Res 85: 1149–1158.

96. HayBA, WolffT, RubinGM (1994) Expression of baculovirus P35 prevents cell death in Drosophila. Development 120: 2121–2129.

97. ShenJ, CurtisC, TavareS, TowerJ (2009) A screen of apoptosis and senescence regulatory genes for life span effects when over-expressed in Drosophila. Aging (Albany NY) 1: 191–211.